Gallium formulation for the treatment and prevention of infectious diseases
US9539233B2 · kind B2 · utility
13Cited by
11References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 3, 2010 |
| Grant date | Jan 10, 2017 |
| Priority date | — |
| Expiry date | Jun 11, 2032 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10T428/2982
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method and composition for treatment of bacterial infections caused by gram negative or gram positive bacteria such as Staphylococcus aureus, Rhodococcus equi, Mycobacterium tuberculosis, Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a formulation containing gallium (III), in a pharmaceutically acceptable salt or complex thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.